Cyberonics Inc. announced that Bruce H. KenKnight, Ph.D., joined the company as its Vice President, Emerging Therapies, effective on January 1, 2013. Dr. KenKnight will lead all of the company's emerging therapies programs, including the current clinical evaluation of Autonomic Regulation Therapy, an emerging therapy for treatment of chronic heart failure that incorporates the company's extensive experience delivering vagus nerve stimulation to more than 100,000 patients world-wide. Most recently, Dr. KenKnight was President and CEO of Valtech Cardio Ltd, a privately-held company developing innovative solutions for surgical and percutaneous mitral valve repair and replacement.